Kenvue Inc. (KVUE) — 分析摘要
Kenvue Inc.(KVUE)的市值为36.92十亿美元,最近一年的营收同比增长了-2.1%。净利润率为9.7%。当前市盈率为22.8倍。
核心要点
- 营收同比变化-2.1%
- 净利润率9.7%
- 市盈率22.8倍
与PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS板块的其他公司相比,KVUE的营收增长为-2.1%,市盈率为22.8倍。
Kenvue Inc. (KVUE)
更新 — ET · 来源 POLYGON
红旗与风险提示重点关注
当前存在需要关注的风险信号,应与估值结果一并解读。
流动比率为 0.98x — 流动负债超过流动资产
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
行业
PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS
员工人数
22,000
总部
SUMMIT, NJ
Exchange
XNYS
基于 3 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$0.83
股息收益率
4.42%
股息历史
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。